Wockhardt under the leadership of Dr Khorakiwala has become the world leader in anti-bacterial research, with 6 of its products having QIDP for the industry.

MUMBAI, India, Sept. 27, 2024 -- Founder Chairman of Wockhardt group, Dr. Habil Khorakiwala was presented the Lifetime Achievement Award at the 10th Integrated Health C Wellbeing Summit at Dubai on Sep 21, 2024 through the hands of Dr. Harsh Vardhan, ex-Union Minister for Health C Family Welfare. The esteemed advisory board recognized the exceptional contributions and lifelong dedication of Dr. Habil Khorakiwala to transform the healthcare landscape in India and globally.

Under the visionary leadership of Dr. Habil Khorakiwala over the period of 25 years, Wockhardt has focused its research efforts in the area of discovering novel medicines for multi-drug resistant infections. This has resulted in a portfolio of 6 novel antibiotics at various stages of clinical development and commercialization, each of which have been granted Qualified Infectious Disease Product status by the US FDA. Wockhardt's flagship novel mechanism based antibiotic, Zaynich (Zidebactam/Cefepime), designed to target extreme-drug resistant Gram negative infections, is undergoing a global Phase 3 study. Zaynich has already saved lives of more than 35 critically ill patients under compassionate use over last one year and is also being evaluated in a clinical study involving patients with documented meropenem-resistant infections.

About Wockhardt Ltd.

We are a leading, research-based, global enterprise with relevance in the fields of pharmaceuticals, biotechnology, and healthcare services.  

Since inception over 5 decades ago, we have pioneered, grown and evolved into an integrated pharmaceutical & healthcare enterprise with a global footprint that accounts for over two thirds of our total sales revenues.

Our multinational R&D and manufacturing facilities are spread across India, USA, UK, Ireland and UAE, and our worldwide marketing presence includes over 30 countries across 6 continents.

Our deep domain expertise and experience; comprehensive R&D competencies and capabilities; a multi-ethnic global workforce; and worldwide presence; helps us manufacture and market pharmaceutical products and provide healthcare services targeting unmet medical needs all over the world.

We are not only dedicated in our efforts and actions, but also hold ourselves responsible for the consequent results. So, while we are driven to accomplish soaring achievements, we are also well grounded by being anchored to core values of ethical behaviour, transparency and doing the right thing. It is our core value system that is perfectly expressed by our corporate credo, LIFE WINS.

For more information please visit: https://www.wockhardt.com/

Photo: https://mma.prnewswire.com/media/2517482/Dr_Habil_Khorakiwala.jpg